Reishi Mushroom for Cancer Risk Reduction

Research suggests that Ganoderma lucidum (reishi mushroom) demonstrates meaningful anticancer potential across a wide range of cancer types, including breast, prostate, colon, lung, cervical, and certain blood cancers, with proposed mechanisms including immune stimulation, inhibition of tumor cell proliferation, promotion of apoptosis, and suppression of metastasis and angiogenesis. The available evidence base consists predominantly of laboratory studies, animal models, and narrative or systematic reviews rather than large-scale randomized controlled trials in humans, which is an important limitation when interpreting the clinical significance of these findings. Several reviews note that reishi's bioactive polysaccharides and triterpenoids appear most active, and that processing methods — such as shell-breaking of spores — may meaningfully affect potency. One safety-relevant finding worth noting is that a 2023 systematic review flagged elevated levels of the cancer antigen CA72-4 at high doses of spore extract, suggesting that while the overall safety profile appears acceptable at typical doses, high-dose use warrants caution and that further human clinical research is needed before definitive conclusions about cancer risk reduction can be drawn.